Q-omics provides the consensus-scored RRP1B profile across patient tissues and cancer cell-line models. RRP1B expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RRP1B is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RRP1B protein abundance shows 28,022 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, COAD, and LUAD as cancer lineages where RRP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRP1B survival associations across molecular data types. RRP1B RNA expression shows survival associations in the most cancer types (30), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRP1B RNA expression–survival associations across cancer types. High RRP1B expression shows unfavorable associations in MESO, KIRP, ACC, CESC and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RRP1B RNA expression.
This table summarizes RRP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RRP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRP1B shows higher tumor expression in COAD, HNSC, STAD, KIRC, LUAD and BLCA. The COAD box plot shows higher RRP1B RNA expression in tumor versus normal tissue (log2 FC = +0.884, t-test p < 0.001).
This table shows molecular features associated with RRP1B in patient tissues and cancer cell lines. In patient samples, RRP1B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RRP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
